Symbeo, Inc. launches latest solution for today’s AP challenges
New platform for enterprise and mid-market-size organizations drives invoice automationPORTLAND, Ore., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Symbeo, Inc., a...
Financial
Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using...
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
The International Myeloma Foundation will work with Amazon’s cloud computing arm to educate patients, understand donors, increase fundraising, and moreSTUDIO...
Syneos Health Releases 2023 Health Trends
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product DevelopmentMORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) --...
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
CERIS Expands Services and Rebrands
Rapidly Growing Payment Integrity Firm Offers New Solutions in DRG Validation, Data Mining and More FORT WORTH, Texas, Nov. 29,...
SmileDirectClub Announces Launch of Innovative SmileMaker Platform
Smile-Changing AI Technology Offers View of New Smiles Through Mobile Devices SmileDirectClub SmileMaker Platform The SmileMaker Platform is now available...
Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform
Company Will Pursue Drug Discovery of Market-Authorized, Finished Pharmaceuticals that Address Demand for Personalized TherapiesFRANKFURT AM MAIN, Germany, Nov. 15,...
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing...
HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratificationSouthlake, Texas, Nov. 10, 2022...
Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE)...
Constant Therapy Health Wins 2022 Hearst Health Prize
Leading Digital Brain Rehabilitation Company Takes Home $100,000 AwardLEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Constant Therapy Health, a...
Myia Health Collaborates with DispatchHealth to Empower Clinicians with Virtual Care Platform for Continuous Patient Monitoring
DispatchHealth clinicians will have access to near real-time insights to optimize patient outcomes and clinical operationsSAN FRANCISCO, Nov. 02, 2022...
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
Guideline adoption can help end the diagnostic odyssey experienced by many families STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) --...
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY...
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
-- Abnormal findings reported in 63% of infants in study, change in health management recommended in 88% of cases ----...
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
Exome and genome tests report 30% fewer inconclusive results and a higher diagnostic yield compared to multi-gene panel tests; research...
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven...
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver...